“Our new CLIA-compliant NGS services, including whole genome sequencing and whole exome sequencing, provide sensitive and unbiased detection of genetic variants enabling clinical researchers to answer focused biological questions using genome-scale information,” said Dr. Haythem Latif, Director, Clinical Development Services at GENEWIZ. “Both our next-gen and Sanger sequencing CLIA-compliant workflows ensure high-quality testing and accurate and consistent results.”
All GENEWIZ CLIA services are performed at its New Jersey-based CLIA-certified laboratory using CLIA-qualified equipment. Service levels can include quality assurance oversight and lab director sign-off. Current CLIA-compliant services include:
The Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing and requires all clinical laboratories be certified by their state and the Center for Medicare and Medicaid Services. The GENEWIZ clinical lab is also accredited by The College of American Pathologists (CAP).
GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in Sanger sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory-compliant services. Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, Tianjin, and Guangzhou, China; Takeley, United Kingdom; Leipzig, Germany; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo.